PSORIATIC ARTHRITIS FLARE UP/HANDS JOINTS SWELLING; Pain; PSORIASIS; This spontaneous case was reported by an other health care professional and describes the occurrence of PSORIATIC ARTHROPATHY (PSORIATIC ARTHRITIS FLARE UP/HANDS JOINTS SWELLING) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    Concurrent medical conditions included Cholesterol, Blood pressure, Acid reflux (oesophageal), Diabetes, Diabetic neuropathy and Psoriatic arthritis. Concomitant products included OMEPRAZOLE for Acid reflux (oesophageal), METOPROLOL for Blood pressure, LOVASTATIN for Cholesterol, INSULIN DETEMIR (LEVEMIR) for Diabetes, GABAPENTIN for Diabetic neuropathy.   In June 2021, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram. On 22-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Sep-2021, the patient experienced PSORIATIC ARTHROPATHY (PSORIATIC ARTHRITIS FLARE UP/HANDS JOINTS SWELLING) (seriousness criterion medically significant), PAIN (Pain) and PSORIASIS (PSORIASIS). The patient was treated with CLOBETASOL at an unspecified dose and frequency and BETAMETHASONE VALERATE (BETAMETHASON [BETAMETHASONE VALERATE]) at an unspecified dose and frequency. At the time of the report, PSORIATIC ARTHROPATHY (PSORIATIC ARTHRITIS FLARE UP/HANDS JOINTS SWELLING), PAIN (Pain) and PSORIASIS (PSORIASIS) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. Primary reporter did not have the lot number information, because the information was not accessible to the physician at his/her clinical setting. The reporter's causality with Humira for the events of HANDS JOINTS SWELLING, PAIN, PSORIASIS and PSORIATIC ARTHRITIS FLARE UP was not provided. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in  Company Comment: This is a Spontaneous case reported by other health care professional, concerning a female patient of unknown age, with relevant medical condition of psoriatic arthritis, who experienced the unexpected and serious (due to medically significant) event of Psoriatic arthropathy (reported as psoriatic arthritis flare up), which occurred 6 days after the first dose of mRNA-1273 vaccine. Patient also experienced hands joint swelling, pain and psoriasis, which could be related to Psoriatic arthritis. She was treated with clobetasol and betamethasone. Co-suspect product includes non-company product Adalimumab for psoriatic arthritis. At the time of the report, the event had not resolved. Psoriatic arthritis can present relapses as part of the natural history of disease, so that confounds the case. The benefit-risk relationship of mRNA-1273 vaccine, is not affected by this report.; Sender's Comments: This is a Spontaneous case reported by other health care professional, concerning a female patient of unknown age, with relevant medical condition of psoriatic arthritis, who experienced the unexpected and serious (due to medically significant) event of Psoriatic arthropathy (reported as psoriatic arthritis flare up), which occurred 6 days after the first dose of mRNA-1273 vaccine. Patient also experienced hands joint swelling, pain and psoriasis, which could be related to Psoriatic arthritis. She was treated with clobetasol and betamethasone. Co-suspect product includes non-company product Adalimumab for psoriatic arthritis. At the time of the report, the event had not resolved. Psoriatic arthritis can present relapses as part of the natural history of disease, so that confounds the case. The benefit-risk relationship of mRNA-1273 vaccine, is not affected by this report.